Introduction
intubation, values of pH, PaCO 2 and respiratory rate at It is now well established that most patients of COPD 1 hr., complication rates and length of hospital stay. with respiratory failure due to acute exacerbation should receive a trial of NIV. [1] Recent metaanalyses of 8 and While early use of NIV is recommended, concerns ex 15 randomized controlled studies respectively [2, 3] showed ist that delay in detecting failure may increase mortal that, compared with usual care, adjunctive NIV therapy ity. [4, 5, 6] Current opinion favors switching to endotracheal was associated with improvements in mortality, need for mechanical ventilation (ETMV) in the event of deterio rating pH, PaCO and persistence of altered sensorium variance with our observations. In the last decade, when the full scope of this form of support was relatively un explored, we found remarkable success with severe exacerbations of COPD where there was no prompt ini tial response to NIV. The threshold for intubation in our group of patients was higher than in current recommen dations. Our later practice was conditioned by key pub lications in subsequent years that cautioned against delaying intubation and by our growing experience with more aggressive support. This account of our early ex perience is to stimulate further exploration of predictive factors relating to success with NIV in subsets of COPD patients presenting with severe respiratory acidosis.
Current Indian experience on the use of NIV in COPD patients is limited to a single abstract. [10] 
Materials and Methods
Patients of COPD managed by one team who received NIV between August 1994 and July 1996 at Batra Hos pital and Medical Research Centre, New Delhi, India.
Care was initiated in the intensive care unit with NIV at admission within a few hours of admission. Standard care included oxygen supplementation, corticosteroids, bronchodilators, antibiotics, rehydration and correction of electrolyte disturbances.
Patients included
The study included patients receiving NIV for acute exacerbation of COPD (based on clinical criteria) in the following circumstances: dyspnoea with respiratory rate (R/R) of >25/mt PaCO 2 of > 60mm Hg and / or arterial pH <7.35;acceptance of NIV; altered sensorium, but not deep coma (encephalopathy score < / = 3)
Patients excluded
Following patients of COPD were considered unsuit able for NIV: respiratory arrest, haemodynamic instabil ity; deeply comatose patient (encephalopathy score > 3); pneumonia; excessive secretions or inability to clear secretions; severe sepsis. Patients of COPD with comorbidities such as obstructive sleep apnea, acute on-chronic renal failure, left ventricular dysfunction, he patic failure, trauma, neurological diseases receiving NIV were excluded.
Ventilators and interface
NIV was applied with either BiPAP STD (Respironics Inc., USA) or Servo 900 B (Siemens, Sweden) volume ventilator. Only nasal masks were used as well-fitting orofacial masks were unavailable; a good fit and mini mal leak were ensured by using a range of mask size and head gear. Chinstraps were used where necessary. "Band-aid" local dressing was applied over bridge of nose at the earliest sign of erythema. Forehead cushions were routine. Nasogastric tubes were not used.
Mode and settings
In most patients bilevel pressure support was applied in the 'S/T' mode. Inspiratory and Expiratory positive air way pressure (IPAP and EPAP) were adjusted thus: EPAP was first adjusted to improve arterial oxygen satu ration to above 90% and then to improve triggering. A minimum EPAP of 4 cm. H 2 O was applied in most pa tients (19 out of 24 episodes). IPAP was then increased in steps of 2 Cms.H 2 O depending on blood gas meas urements and patient tolerance. Timed breaths of 12 15 breaths/min were used as 'back up' ventilation during night time support when hypercapnia was difficult to con trol. A few patients received NIV with a volume ventilator as portable bilevel pressure ventilators were unavailable. The tidal volume in the latter situation was set at 10ml/ kg and the rate set at 12 breaths /minute [ Table 1 ].
Duration of support
NIV was applied continuously for as many hours/day as tolerated until sensorium returned to normal, comfort was restored, and blood gas measurements stabilized. Masks were removed for feeding and toilet.
Intubation criteria
NIV failure was recognized if there was: deteriorating level of consciousness after 2 hours of support, hemodynamic instability, persistent hypoxemia <88% despite high-flow oxygen supplementation (>10 l/min through ventimask), exhaustion and inability to synchro nize with NIV and vomiting or upper gastrointestinal haemorrhage. Late failure requiring intubation was iden tified when sensorium or dyspnoea worsened despite increasing NIV support for 2 hours after the change in clinical status. Biochemical deterioration alone (i.e., ris ing PaCO 2 and fall in pH) without clinical deterioration was not an indication for intubation.
Measurements
Respiratory rate, heart rate, arterial blood pressure, continuous pulse oximetry, encephalopathy score, hourly temperature and urine output.
The mental state was scored from 0 -4 (modified Par sons-Smith criteria) (11) for encephalopathy: grade 0 -no abnormality; grade I -trivial lack of awareness, anxi ety, shortened attention span; grade 2 -lethargy, tremor, asterixis, disorientation, personality change, inappropri ate behaviour; grade 3 -somnolence to semistupor, responsive to stimuli, confused, gross disorientation and agitation; grade 4 -coma.
Blood gases were measured at 1 hour and 3 -8 hours after application of NIV and every morning thereafter, or if there was clinical deterioration. Both baseline PaCO 2 and pH values and their worst values in the clinical course were recorded. Oxygen supplementation was given to all patients starting at 1-2L/mt adjusting flow to maintain SPO of 88-92%. 2 Biochemical tests conducted at admission and there after periodically included: blood sugar, renal profile, electrolytes and liver function tests. Chest X-rays were performed daily in the initial unstable period.
Success or Failure of NIV
NIV was deemed successful if: 1) Patient was discharged without intubation after at least two days of clinical (alertness with no dyspnea) and biochemical stability (pH>7.35, PaCO 2 55-65 mmHg) without support. 2) Patient was discharged from hospital to continued nocturnal NIV home support without intubation after at least two days of clinical and biochemical stability. Statistical analysis statistical analysis was performed using the Wilcoxon Signed Ranks test for non-parametric data.
Results
During the study period, a total of 44 patients admitted under one team were given NIV support either in the medical intensive care unit or wards depending on ill ness severity [ Table 2 ].
The study group included 10 women and 7 men with a mean age of 59.5 years (range 48 -82). All patients had severe hypercapnia: mean peak (i.e., the worst) PaCO 2 89 ± 21 mm Hg (range 66 -143) with severe respiratory acidosis: mean nadir (i.e., the worst) pH 7.24 ± 0.058 (range 7.14 -7.33). All had tachypnoea -mean respiratory rate of 29.5 ± 4.69/mt (range 24 -40). In 17 episodes, there was altered mental status with an En cephalopathy score of grade 3 in 13 episodes and grade 2 in 4 episodes [ Table 1 ]. The mean encephalopathy score at admission was 1.92 ± 1.32 (median 2.5). The mean time on NIV was 16.5 hrs/day (range [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . Clini cal stability occurred over several days: mean 13 ± 9.6 days (range 5-40).
After NIV, there was initially a rise in the PaCO 2 levels in all patients. The mean baseline (immediately before NIV) PaCO 2 levels, was 64.7± 14.2 mm Hg (range 46.5 -98.6). Post NIV PaCO 2 rose to peak levels of 89.0 ± 21 mm Hg (range 66 -143). There was significant dif ference between the baseline and peak PCO2 levels (20.7 ± 18.4 mm Hg P <0.001) [ Figure 1 ]. Correspond ingly, the pH fell from a mean baseline value of 7.330 ± 0.96 to a mean nadir level of 7.24 ± 0.58 (P<0.001) [Fig  ure 2 ]. The mean IPAP was 15.43 ± 0.62 and mean EPAP was 5.81± 0.62. NIV was successful in 22 out of 24 episodes (91.67%). The final PaCO 2 levels at discharge in these 22 episodes decreased significantly to a mean level of 56.16 ± 9 mm 1  100  40  70  76  80  95  60  64  2  70  65  100  60  65  85  60  55  3  79  75  90  100  78  70  66  59  4  60  140  125  90  130  125  100  80  5  80  85  75  100  705  90  83  70  6  75  70  80  100  95  101  80  75 Hg as compared to the peak PaCO 2 levels (P<0.001). of success would facilitate accurate patient selection, The final pH rose significantly to 7.375 ± 0.06, as com determine the setting for its application and the timing of pared to nadir values (P<0.001). The mean encepha intubation when the risk of failure is high. [3, 7, 9, 13] lopathy score after 24 hours was 0.70 ± 0.88 with a median of 0. The difference between mean baseline and This review of our earliest experience with NIV focuses 24-hour encephalopathy scores was significant (P = on the criteria that are said to be predictive of outcome. 0.001).
The severity of respiratory acidosis at the outset is re ported to be predictive of NIV failure. Ambrosino et al [4] The respiratory rate was significantly reduced from 29.5 in a retrospective review of COPD patients found that ± 4.69/mt at baseline to 22.3 ± 2.1/mt after NIV lower baseline PaCO 2 values (79 vs. 98) and higher pH (P<0.001). values (7.28 vs. 7.22) correlated with success. This was confirmed in other prospective randomized studies, [12, 13] In 6 of the episodes where the peak PaCO 2 levels were but not in all. [14, 15, 16] 100 mm Hg or more NIV was successful and the pa tients could be discharged to nocturnal home NIV supHypercapnia in this study (mean peak PaCO 2 89 ± 21 port [ Figure 2 and Table 3 ]. Two patients out of the 17 mm Hg, range 66 -143) is among the highest levels died, one after intubation and mechanical ventilation for reported hitherto. [3, 16, 17, 18] The acuity of the exacerbations 15 days following a trial of NIV for 2 days, and the other is also reflected in the presence of severe respiratory while receiving NIV, as she refused intubation. acidosis (mean nadir pH 7.24 ± 0.058, range 7.14 -7.33). NIV was successful in 22 out of the 24 episodes (91.67%) No correlation was found between initial pH and PaCO 2 testifying to its remarkable efficacy. Notably, in all of the with the degree of encephalopathy or with response to 6 episodes with PaCO 2 more than 100 mm Hg, NIV was NIV.
successful. Previous reports have shown a success rate of 71-96% [9, 12, 15, 13, 19] in patients with lesser degrees of Few complications occurred in this series. One patient respiratory acidosis. who was indeed the first case to be supported with NIV developed a deep ulcer on the bridge of the nose. NotaThe level of consciousness (LC) at admission has been bly this patient was ventilated with a volume ventilator used to predict outcome. Most studies [3] and guide and a less sophisticated mask than presently available. lines [8, 20] excluded patients with altered sensorium due One patient had gastric distension that settled with re to theoretical concerns about the risk of aspiration. Base duction in pressures and time on NIV support.
line LC and pH values have been reported to correlate with success. [4, 9, 13, 16] In the study by Brochard et al, [12] Discussion the encephalopathy score among patients in the NIV NIV has been studied extensively in the context of acute group who needed intubation was 1.9 ± 1.2. Based on exacerbation of COPD and several RCTs have proved data from 1,033 patients Confalonieri et al [9] have devel its efficacy. [2, 3] NIV has not been universally successful, oped a risk prediction model in which GCS<11 and pH with reported failure rates of 7-50% due mainly to the <7.25 correlate with the highest risk of failure. Contrary heterogeneity of the study population. [3] There are con to this view in our series with a high rate of success, cerns about incorrect selection of patients leading to disturbed consciousness was present in 17 of the 24 delay in intubation. [4, 5, 6] Understanding the determinants episodes (mean ES 1.92, median 2.5).
Several others have shown successful outcome in this group of patients. Benhamou et al [21] showed a relatively high success rate of 65% in elderly patients with drowsi ness, agitation or coma. Intermittent negative pressure ventilation had a high rate of success in the presence of coma (GCS range 3-8). [22] Other studies [23, 24] have also found no impact of baseline sensorium on patients' re sponse to NIV. More recently, Gonzalez-Diaz et al [18] showed that hypercapnic coma with GCS < 8 can be treated as successfully as awake patients with NIV. The largest subgroup in this series was also COPD in which the success rate of those with severe encephalopathy was 86%, similar to our results.
Once initiated, the response to NIV may also indicate the chances of success. Studies suggest that this can be gauged early within the first 4 hours. In the study by Ambrosino et al [4] physicians intubated patients if the pH value remained < 7.35 after 1-2 hrs of NIV. However, after using logistic regression analysis only the baseline pH had a reliable predictive effect among several vari ables. Moreover, there was no control group of patients with different threshold values for intubation to substan tiate this conclusion. Further, pneumonia was far more frequent among those who failed NIV trial as compared to those who succeeded.
In our study, patients with worsening levels of PaCO and pH initially after NIV had successful outcomes when support was continued for more sustained periods. Pa tients of pneumonia were not selected for our study.
In our series it was frequently observed that while the patients were on NIV, paradoxically, the PaCO 2 levels rose initially, and this difference between the baseline and peak levels was highly significant (P<0.001).
Many prospective studies have demonstrated remark able reduction of PaCO 2 and pH levels within the first few hours [13, 15, 25, 26, 27] and the failure of this to occur has been regarded as a predictor of unsuccessful out come. [4, 9, 13] Benhamou et al [21] noticed that the PaCO and pH levels remained unchanged during the first hour, but improved later. Meecham Jones et al [28] found that the most severely hypercapnic patients showed a rise in PaCO with the addition of nasal ventilation. In our 2 series, all were severely hypercapnic, with possible pre existing chronic stable respiratory failure, showing simi lar initial worsening. We also found that the PaCO 2 lev els fluctuated considerably for a variable period (hours days) before settling down to stable levels [ Figure 3 ]. The average period for clinical and biochemical stability was 13 ± 9.6 days (range 5 -40).
Despite the initial rise in PaCO 2 often to alarming lev els, we persevered with NIV because the patients were clinically better or without deteriorating sensorium. This is in contrast to studies discussed above where support was escalated to invasive ventilation when the expected biochemical response did not occur in the initial hours. Sensorium and dyspnoea in our study improved over several hours even while the blood gas levels were grossly abnormal. Attention to compliance with NIV or mask fit often produced a favorable response in those who had clinical deterioration after initial improvement. In all cases, the inspiratory pressure and the duration of NIV were increased to the maximum tolerated to improve ventilation. A minimum EPAP of 4cms H 2 O was applied in most episodes which would perhaps have reduced the chances of carbon-dioxide rebreathing, as a stand ard whisper swivel was used. [29] The higher success rate in our series is attributable to a more sustained and aggressive application of NIV to gether with a disregard for worsening PaCO and pH, if 2 2 the clinical state in terms of sensorium and dyspnoea was stable or improving.
This raises a possibility (hitherto not studied or defined accurately) that the trial period for NIV was far too short in the preceding studies and that longer trials can be safely attempted in patients of COPD.
Possible mechanisms for the paradoxic initial rise in PaCO 2 after NIV may be a combination of several fac tors including resetting of the respiratory drive to high PaCO 2 levels in chronic stable hypercapnic failure, [30] loss of hypoxic drive after oxygenation, reduction of minute ventilation from NIV-induced resistive loading of the up 2 per airway [31] and a rebound increase in REM sleep with reduction of alveolar ventilation. [32] The net effect would be a rise in the PaCO 2 , although the patient is better rested. Improvement in sensorium despite increasing hypercapnia suggests that other factors such as fatigue may also influence mental alertness.
The decision to intubate patients of COPD is always a difficult one because of the high risk of complications, and the possibility of prolonged mechanical ventilation with attendant morbidity and mortality. In the Third World, given the high cost of intensive care and the scarcity of ventilators this decision is even more difficult. It is dis appointing that out of those who can be weaned from invasive ventilation only 38% -56% survive at the end of one year [33, 34] questioning the overall cost-effective ness of prolonged mechanical ventilation. Often the fam ily, when informed of the uncertain course and the ex penses involved, is reluctant to consent to invasive ven tilation. For these reasons, the decision for ventilatory support often poses a moral dilemma in those with ad vanced chronic disability who present with acute respi ratory decompensation. The trial with NIV should there fore be aggressive and should not be prematurely aban doned, taking care that intubation, if considered an op tion, is not delayed. Experience with this series of pa tients suggests that longer trials of NIV can be safely attempted in a subset who may improve clinically while they may temporarily worsen in terms of biochemical parameters.
Although the patients in this series were spared the problems of prolonged invasive mechanical ventilation, they, nevertheless required prolonged support with NIV. This, in contrast to invasive support was associated with few serious complications. With close monitoring, good mask fit, trained personnel and skilful handling of pa tients high success rates can be achieved.
The main limitation of the study is that it is retrospec tive. However, given the well-proven efficacy of NIV in the setting of COPD patients a prospective, randomized study with controls supported invasively without prior trial of NIV cannot be ethically supported. It would appear that the current recommendations for predicting failure of NIV might not be accurate for an individual patient. The question of the optimal duration of trial can perhaps be addressed by a randomized controlled trial compar ing different cut-off points for switching from noninvasive to invasive ventilation, rather than using pre-defined rigid and arbitrary criteria for intubation. Our observations certainly challenge the currently accepted boundaries set for NIV since a high proportion of this series of pa tients with altered sensorium and initially deteriorating biochemical parameters went on to have a favorable outcome.
Conclusions
In selected patients of COPD with severe hypercapnia and respiratory acidosis, NIV may be continued even if PaCO 2 and pH deteriorate initially provided there is im provement in clinical status as reflected by sensorium and degree of respiratory distress. As there may be a an initial worsening of PaCO 2 and pH without signifying failure of NIV, these values alone should not influence the decision to escalate treatment to invasive support. This decision may be more reliably based on clinical sta tus parameters. The tolerable thresholds for NIV trial may be set too low and need further study.
